AB
HRTX icon

Amalgamated Bank’s Heron Therapeutics HRTX Stock Holding History

Amalgamated Bank’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,827
Closed -$6K – 2170
2025
Q4 		$6K Buy
4,827
+780
+19% +$963 ﹤0.01% 2641
2025
Q3 		$5K Hold
4,047
– – ﹤0.01% 2763
2025
Q2 		$8K Hold
4,047
– – ﹤0.01% 2526
2025
Q1 		$9K Buy
4,047
+443
+12% +$860 ﹤0.01% 2426
2024
Q4 		$6K Hold
3,604
– – ﹤0.01% 2661
2024
Q3 		$7K Hold
3,604
– – ﹤0.01% 2619
2024
Q2 		$13K Hold
3,604
– – ﹤0.01% 2305
2024
Q1 		$10K Sell
3,604
-10,841
-75% -$27.3K ﹤0.01% 2443
2023
Q4 		$25K Sell
14,445
-1,073
-7% -$1.18K ﹤0.01% 2554
2023
Q3 		$16K Hold
15,518
– – ﹤0.01% 2750
2023
Q2 		$18K Buy
15,518
+1,117
+8% +$1.99K ﹤0.01% 2788
2023
Q1 		$22K Sell
14,401
-2,160
-13% -$5.41K ﹤0.01% 2605
2022
Q4 		$41K Hold
16,561
– – ﹤0.01% 2506
2022
Q3 		$70K Buy
16,561
+266
+2% +$1.04K ﹤0.01% 2317
2022
Q2 		$45K Buy
16,295
+1,252
+8% +$5.03K ﹤0.01% 2541
2022
Q1 		$86K Sell
15,043
-1,268
-8% -$9.28K ﹤0.01% 2250
2021
Q4 		$149K Sell
16,311
-177
-1% -$1.81K ﹤0.01% 2014
2021
Q3 		$176K Sell
16,488
-959
-5% -$11.7K ﹤0.01% 2015
2021
Q2 		$271K Buy
17,447
+4,984
+40% +$79.3K ﹤0.01% 1929
2021
Q1 		$202K Sell
12,463
-1,240
-9% -$22.1K 0.01% 1484
2020
Q4 		$290K Buy
13,703
+77
+0.6% +$1.34K 0.01% 1245
2020
Q3 		$202K Sell
13,626
-403
-3% -$6.29K 0.01% 1318
2020
Q2 		$206K Sell
14,029
-1,084
-7% -$17.8K 0.01% 1289
2020
Q1 		$177K Sell
15,113
-535
-3% -$10.1K ﹤0.01% 1400
2019
Q4 		$368K Buy
15,648
+2,631
+20% +$58.2K 0.01% 1292
2019
Q3 		$241K Sell
13,017
-197
-1% -$3.63K 0.01% 1449
2019
Q2 		$246K Buy
13,214
+2,667
+25% +$53.3K 0.01% 1474
2019
Q1 		$258K Buy
10,547
+419
+4% +$11K 0.01% 1352
2018
Q4 		$263K Buy
+10,128
New +$278K 0.01% 1251
2018
Q3 		– Sell
-9,745
Closed -$379K – 1525
2018
Q2 		$379K Buy
+9,745
New +$310K 0.01% 1179

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Amalgamated Bank's HRTX Position: Q1 2026 in Review

Amalgamated Bank sold out of Heron Therapeutics (HRTX) in Q1 2026, closing a stake of 4,827 shares — an estimated $6K sold.

Amalgamated Bank first reported a position in HRTX in Q2 2018 and held it in 30 quarters. The position peaked at $379K in Q2 2018. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Amalgamated Bank reported no remaining Heron Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 4,827 Heron Therapeutics shares in Q1 2026, an estimated $6K.
  • Amalgamated Bank first reported a position in Heron Therapeutics in Q2 2018 and held it in 30 quarters.
  • Amalgamated Bank's Heron Therapeutics position peaked at $379K in Q2 2018.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.